Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wall Street ekes out gains to close languid week

06/11/2021 | 04:20pm EDT
The Wall St. sign is seen near the NYSE in New York

NEW YORK (Reuters) - U.S. stocks closed modestly higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.

The Nasdaq gained the most among the three major indexes, while the bellwether S&P 500 squeaked its way to a second straight record closing high.

For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a small weekly loss.

The indexes have been range-bound, with few catalysts to move investor sentiment. Much of the focus centered on Thursday's consumer price data, which eased jitters over the duration of the current inflation wave.

"It's a muted day today," Oliver Pursche, senior vice president at Wealthspire Advisors, in New York. "The summer is settling in, people are slipping out of work early and there's nothing in the news that's going to materially drive the market in either direction."

"So, investors are going to wait until earnings season."

The Federal Reserve has repeatedly said that near-term price surges will not metastasize into lasting inflation, an assertion reflected in the University of Michigan's Consumer Sentiment report released on Friday, which showed inflation expectations easing from last month's spike.

Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates.

"Our view continues to be that inflationary data is transient and we will be around the 2% mark for the year," Pursche added.

Benchmark U.S. Treasury yields posted their biggest weekly drop in nearly a year, weighing on the interest-sensitive financial sector in recent sessions.

The Food and Drug Administration is facing mounting criticism over its "accelerated approval" of Biogen Inc's Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease.

Biogen shares ended down 4.4%, while the broader healthcare sector shed 0.7%.

The Dow Jones Industrial Average rose 13.36 points, or 0.04%, to 34,479.6, the S&P 500 gained 8.26 points, or 0.19%, to 4,247.44 and the Nasdaq Composite added 49.09 points, or 0.35%, to 14,069.42.

Among the 11 major sectors in the S&P 500, rebounding financial stocks and tech led the gainers, while healthcare suffered the biggest percentage drop.

Much of the trading volume this week was attributable to the ongoing social media-driven "meme stock" phenomenon, in which retail investors swarm around heavily shorted stocks.

But meme stock moves were more muted on Friday, with AMC Entertainment outperformed, gaining 15.4%.

Advancing issues outnumbered declining ones on the NYSE by a 1.83-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.

The S&P 500 posted 33 new 52-week highs and one new low; the Nasdaq Composite recorded 108 new highs and 16 new lows.

Volume on U.S. exchanges was 9.11 billion shares, compared with the 10.56 billion average over the last 20 trading days.

(Reporting by Stephen Culp in New York; Additional reporting by Ambar Warrick and Devik Jain in Bengaluru; Editing by Matthew Lewis and Cynthia Osterman)

By Stephen Culp


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AMC ENTERTAINMENT HOLDINGS, INC. 10.06% 60.73 Delayed Quote.2,764.62%
BIOGEN INC. -1.99% 383.52 Delayed Quote.56.63%
DJ INDUSTRIAL -0.62% 33823.45 Delayed Quote.12.07%
NASDAQ COMP. 0.87% 14161.350236 Delayed Quote.8.93%
S&P 500 -0.04% 4221.86 Delayed Quote.12.45%
All news about BIOGEN INC.
10:58aSage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zu..
AQ
10:57aBIOGENá : Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-T..
AQ
08:01aBIOGENá : Doses First Patient in Late-Stage Study of Lupus Drug Candidate
MT
07:30aBIOGENá : Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus ..
AQ
04:31aROCHEá : Syncona CFO to Retire; Three New Executives Named
MT
06/16Biogen to Discontinue Clinical Development of Potential Treatment for Alzheim..
DJ
06/16BIOGENá : Scraps Work on Potential Alzheimer's Disease Treatment After Drug Cand..
MT
06/16STREET COLOR : Biogen Says Gosuranemab Did Not Meet Primary Goal in Phase 2 Stud..
MT
06/16Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-T..
GL
06/16EISAIá : First patient receives controversial Biogen Alzheimer's drug
RE
More news
Financials (USD)
Sales 2021 10 630 M - -
Net income 2021 2 211 M - -
Net Debt 2021 1 184 M - -
P/E ratio 2021 27,3x
Yield 2021 -
Capitalization 57 741 M 57 741 M -
EV / Sales 2021 5,54x
EV / Sales 2022 5,06x
Nbr of Employees 9 100
Free-Float 85,8%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 417,86 $
Last Close Price 391,31 $
Spread / Highest target 65,3%
Spread / Average Target 6,78%
Spread / Lowest Target -37,6%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.59.81%58 914
CSL LIMITED6.72%106 239
WUXI BIOLOGICS (CAYMAN) INC.17.51%63 571
SAMSUNG BIOLOGICS CO.,LTD.0.85%49 265
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.20.95%45 015
ALEXION PHARMACEUTICALS, INC.15.56%39 905